C&EN reported that the NIH-funded AViDD/ASAP center associated with PostEra was slated to run out of money in a few months, creating funding uncertainty for one of the company’s collaborative programs.
SourcePublic company, workplace, funding, and market signals
AI-first biotechnology company focused on medicinal chemistry drug discovery; Proton combines molecular design, synthesis-aware planning, and active learning to accelerate small-molecule programs for pharma partners and PostEra's internal women’s health/fertility pipeline.
Primary product
Proton, an end-to-end machine-learning platform for medicinal chemistry and drug discovery
Founded
2019
Headquarters
Boston, Massachusetts, United States
Team size
11-50 employees
Work style
Remote
Industry
Biotechnology Research
Sub-industry
AI drug discovery / medicinal chemistry platform
Offices
2 jobs at PostEra
Business model
Stage
Series A
Total raised
$26.5M
Latest round
Grant · May 2022
Latest amount
$68M
Leadership
CEO & Co-Founder
Co-Founder & Chief Scientific Officer
Matthew Robinson
Co-Founder & Chief Technology Officer
Head of Machine Learning
Head of Medicinal Chemistry
Ricardo Azziz
Acting Chief Medical Officer
Rachael Springer
People Operations Lead
Minimalist, low-hierarchy, cross-disciplinary culture with drug hunters, scientists, ML researchers, and engineers working together; hiring is human-reviewed, and the company emphasizes proportional compensation and internal recognition.
Work style
Remote
Visa sponsorship
No
Compensation
Lead Software Engineer posting showed $190k-$220k salary plus 0.10%-0.20% equity; the company also emphasizes proportional compensation and internal recognition.
Benefits
Pricing
Partner-funded R&D with upfront payments, milestones, and tiered royalties; internal pipeline development alongside collaboration revenue.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$10M-$25M
Estimated monthly visits
1.4K
Traffic estimate as of Jun 2026
C&EN reported that the NIH-funded AViDD/ASAP center associated with PostEra was slated to run out of money in a few months, creating funding uncertainty for one of the company’s collaborative programs.
SourceC&EN · Jun 2026
Profile of PostEra’s AI-first drug discovery model, its cofounders, partnerships with Pfizer/Amgen/NIH, open-science roots, internal women’s health pipeline, and plans to raise a Series B.
C&EN · Jan 2025
Independent reporting on the Pfizer/PostEra expansion, the ADC focus, and the company’s note that NIH AViDD funding was nearing exhaustion.
PRNewswire · Jan 2025
Official announcement of a new ADC collaboration with Pfizer, a $12M upfront payment, and an expanded collaboration value up to $610M.
PostEra · Mar 2024
Official update that the Pfizer AI Lab had advanced programs faster than forecast and had nominated an additional target.
Endpoints News · Nov 2023
Reported Amgen’s deal with PostEra for five small-molecule programs and described PostEra as having surpassed $1B in collaboration value across partners.